GPT Healthcare reports 12% revenue growth in 9M FY26, strengthens clinical capabilities
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Glucon-D maintained its leadership position with a 59% MAT market share
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated